The complex role of RhoA in regulating vascular smooth muscle cell phenotype in Type 2 diabetes

Abstract

The incidence of type 2 diabetes mellitus (T2DM) is growing globally, and the major cause of morbidity and mortality in these patients is the premature development of cardiovascular disease. Consequently, medical interventions, such as coronary artery bypass graft surgery and widespread statin prescriptions, are common in this patient group. Smooth muscle cells are the major structural component of the vascular wall. They play a crucial role in post-bypass recovery to successfully revascularize the heart by switching between differentiated (contractile) and dedifferentiated (synthetic) phenotypes. However, in patients with T2DM, these cells have functional defects that may affect bypass integration. RhoA is a small GTPase that regulates many functions, such as motility and phenotypic regulation of smooth muscle cells. RhoA is dependent upon a stimulus, and it can drive the contractile smooth muscle cell phenotype present in the healthy condition or the (mal)adaptive phenotypes prevalent in disease or in response to injury. We hypothesize that RhoA deregulation plays a major role in vascular complications of T2DM. This protein is deregulated in T2DM smooth muscle cells, which may in part explain the functional defects of smooth muscle tissue and the subsequent failure rate of bypass in these patients. An important consideration in this circumstance is the use of statin therapies because these further inhibit RhoA activity. The effect of inhibition of RhoA activity in patients with T2DM who have a bypass is currently unknown.

Keywords

Type 2 diabetes / smooth muscle cell / phenotype / RhoA / contractile / synthetic / statins

References

[1] Khan MAB,King JK,Mustafa H.Epidemiology of type 2 diabetes - global burden of disease and forecasted trends.J Epidemiol Glob Health2020;10:107-11 PMCID:PMC7310804

[2] Dal Canto E,Rydén L.Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications.Eur J Prev Cardiol2019;26:25-32

[3] Riches-Suman K.Identifying and targeting the molecular signature of smooth muscle cells undergoing early vascular ageing.Biochim Biophys Acta Mol Basis Dis2022;1868:166403

[4] Mack CP.Signaling mechanisms that regulate smooth muscle cell differentiation.Arterioscler Thromb Vasc Biol2011;31:1495-505 PMCID:PMC3141215

[5] Ghaleb AM.Krüppel-like factor 4 (KLF4): What we currently know.Gene2017;611:27-37 PMCID:PMC5391259

[6] Beamish JA,Kottke-Marchant K.Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.Tissue Eng Part B Rev2010;16:467-91 PMCID:PMC2943591

[7] Christen T,Bochaton-piallat M.Mechanisms of neointima formation and remodeling in the porcine coronary artery.Circulation2001;103:882-8

[8] Kocher O,Gabbiani G.Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening. Biochemical and morphologic studies.Lab Invest1991;65:459-70

[9] Cheng C,Zheng C,Li E.Role of small GTPase RhoA in DNA damage response.Biomolecules2021;11:212 PMCID:PMC7913530

[10] Ngo ATP,Aslan JE.Rho GTPase regulation of reactive oxygen species generation and signalling in platelet function and disease.Small GTPases2021;12:440-57 PMCID:PMC8583099

[11] Tkach V,Berezin V.The role of RhoA in the regulation of cell morphology and motility.Cell Motil Cytoskeleton2005;61:21-33

[12] Solski PA,Keely PJ,Der CJ.RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification.Cell Growth Differ2002;13:363-73 PMCID:PMC4415366

[13] Guan R,Chen M.Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.Eur J Med Chem2013;70:613-22

[14] Loirand G,Bril A.Rho exchange factors in the cardiovascular system.Curr Opin Pharmacol2008;8:174-80

[15] Loirand G,Pacaud P.RhoA and resistance artery remodeling.Am J Physiol Heart Circ Physiol2005;288:H1051-6

[16] Li M,Xin W.The emerging role of Rho guanine nucleotide exchange factors in cardiovascular disorders: insights into atherosclerosis: a mini review.Front Cardiovasc Med2021;8:782098 PMCID:PMC8761945

[17] Yu L,Garg HG.Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/Rho kinase/p27.Am J Respir Cell Mol Biol2011;44:524-30 PMCID:PMC3095924

[18] Moon S.Rho GTPase-activating proteins in cell regulation.Trends in Cell Biology2003;13:13-22

[19] Huang GH,Li HJ.Rho GTPase-activating proteins: regulators of Rho GTPase activity in neuronal development and CNS diseases.Mol Cell Neurosci2017;80:18-31

[20] Tcherkezian J.Current knowledge of the large RhoGAP family of proteins.Biol Cell2007;99:67-86

[21] Amano M,Nakamura N,Matsuura Y.The COOH terminus of Rho-kinase negatively regulates rho-kinase activity.J Biol Chem1999;274:32418-24

[22] Kimura K,Amano M.Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase).Science1996;273:245-8

[23] Loirand G.The role of Rho protein signaling in hypertension.Nat Rev Cardiol2010;7:637-47

[24] Mueller BK,Teusch N.Rho kinase, a promising drug target for neurological disorders.Nat Rev Drug Discov2005;4:387-98

[25] Garcia-Mata R,Burridge K.The “invisible hand”: regulation of RHO GTPases by RHOGDIs.Nat Rev Mol Cell Biol2011;12:493-504 PMCID:PMC3260518

[26] Nagar H,Lee I.CRIF1 deficiency suppresses endothelial cell migration via upregulation of RhoGDI2.PLoS One2021;16:e0256646 PMCID:PMC8389428

[27] Dovas A.RhoGDI: multiple functions in the regulation of Rho family GTPase activities.Biochem J2005;390:1-9 PMCID:PMC1184558

[28] Ahmad Mokhtar AMB, Ahmed SBM, Darling NJ, Harris M, Mott HR, Owen D. A complete survey of RhoGDI targets reveals novel interactions with atypical small GTPases.Biochemistry2021;60:1533-51

[29] Riches-Suman K.Diverse roles of microRNA-145 in regulating smooth muscle (dys)function in health and disease.Biochem Soc Trans2021;49:353-63

[30] Feng MB,Dou FF.Long-chain non-coding RNA LOC554202 promotes proliferation, migration, and invasion of nasopharyngeal carcinoma cells by binding to microRNA-31 expression and regulating RhoA expression.Eur Rev Med Pharmacol Sci2020;24:10550-6

[31] Korourian A,Shariftabrizi A.MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.Exp Biol Med2017;242:1842-7 PMCID:PMC5714140

[32] Wang BG,Liu YF.MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839.Tumour Biol2017;39:1010428317719577

[33] Wang H,Jian Q.MicroRNA-340 inhibits squamous cell carcinoma cell proliferation, migration and invasion by downregulating RhoA.J Dermatol Sci2018;92:197-206

[34] Li Y,Shan Z.Involvement of microRNA-133a in the development of arteriosclerosis obliterans of the lower extremities via RhoA targeting.J Atheroscler Thromb2015;22:424-32

[35] Liu L,Chen X.Role of miR-124 and miR-141 in the regulation of vascular reactivity and the relationship to RhoA and Rac1 after hemorrhage and hypoxia.Am J Physiol Heart Circ Physiol2016;310:H206-16

[36] Chung DJ,Yang MY,Lee HJ.Nelumbo nucifera leaf polyphenol extract and gallic acid inhibit TNF-α-induced vascular smooth muscle cell proliferation and migration involving the regulation of miR-21, miR-143 and miR-145.Food Funct2020;11:8602-11

[37] Fujisawa K,Ishizaki T,Narumiya S.Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase.J Biol Chem1996;271:23022-8

[38] Loirand G,Pacaud P.Rho kinases in cardiovascular physiology and pathophysiology.Circ Res2006;98:322-34

[39] Nakagawa O,Ishizaki T,Nakao K.ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice.FEBS Lett1996;392:189-93

[40] Mong PY.Activation of Rho kinase isoforms in lung endothelial cells during inflammation.J Immunol2009;182:2385-94

[41] Cheng C,Xu DL.Increased ROCK1 not ROCK2 in circulating leukocytes in rats with myocardial ischemia/reperfusion.Perfusion2020;35:819-25 PMCID:PMC8170661

[42] Chevrier V,Collomb N.The Rho-associated protein kinase p160ROCK is required for centrosome positioning.J Cell Biol2002;157:807-17 PMCID:PMC2173415

[43] van Nieuw Amerongen GP, van Hinsbergh VW. Cytoskeletal effects of Rho-like small guanine nucleotide-binding proteins in the vascular system.ATVB2001;21:300-11

[44] Tojkander S,Lappalainen P.Actin stress fibers - assembly, dynamics and biological roles.J Cell Sci2012;125:1855-64

[45] Maekawa M,Boku S.Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase.Science1999;285:895-8

[46] Leung T,Manser E.The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton.Mol Cell Biol1996;16:5313-27 PMCID:PMC231530

[47] Watanabe N,Reid T.p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin.EMBO J1997;16:3044-56 PMCID:PMC1169923

[48] Saito K,Kurihara H,Hattori S.Afadin regulates RhoA/Rho-associated protein kinase signaling to control formation of actin stress fibers in kidney podocytes.Cytoskeleton2015;72:146-56

[49] Miralles F,Zaromytidou A.Actin dynamics control SRF activity by regulation of its coactivator MAL.Cell2003;113:329-42

[50] Hill CS,Treisman R.The Rho family GTPases RhoA, Racl, and CDC42Hsregulate transcriptional activation by SRF.Cell1995;81:1159-70

[51] Mack CP,Hautmann M,Owens GK.Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization.J Biol Chem2001;276:341-7

[52] Ai S,Koike T.Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways.Atherosclerosis2001;155:321-7

[53] Qi Y,Dai F,Sun J.RhoA/ROCK pathway activation is regulated by AT1 receptor and participates in smooth muscle migration and dedifferentiation via promoting actin cytoskeleton polymerization.Int J Mol Sci2020;21:5398 PMCID:PMC7432407

[54] Pescatore LA,Forti FL,Kovacic H.Protein disulfide isomerase is required for platelet-derived growth factor-induced vascular smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase activation.J Biol Chem2012;287:29290-300 PMCID:PMC3436193

[55] Tang L,Liu Y.RhoA/ROCK signaling regulates smooth muscle phenotypic modulation and vascular remodeling via the JNK pathway and vimentin cytoskeleton.Pharmacol Res2018;133:201-12

[56] Zhuge Y,Qian F.Role of smooth muscle cells in cardiovascular disease.Int J Biol Sci2020;16:2741-51 PMCID:PMC7586427

[57] Riches K,Maqbool A.Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms.Int J Biochem Cell Biol2013;45:1776-83 PMCID:PMC3731554

[58] Jain M.Role of integrins in modulating smooth muscle cell plasticity and vascular remodeling: from expression to therapeutic implications.Cells2022;11:646 PMCID:PMC8870356

[59] Hayfron-Benjamin C,Maitland-van der Zee AH.Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: the RODAM study.J Diabetes Complications2019;33:572-8

[60] Khanam PA,Begum T,Latif ZA.Microvascular complications and their associated risk factors in type 2 diabetes mellitus.Diabetes Metab Syndr2017;11 Suppl 2:S577-81

[61] Jin J,Zhi X.Epigenetic regulation in diabetic vascular complications.J Mol Endocrinol2019;63:R103-15

[62] Contreras F,Vasquez J,Velasco M.Diabetes and hypertension physiopathology and therapeutics.J Hum Hypertens2000;14 Suppl 1:S26-31

[63] DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview.Diabetes Care2014;37:9-16 PMCID:PMC3867999

[64] Ohri SK,Luthra S.Coronary artery bypass surgery in the UK, trends in activity and outcomes from a 15-year complete national series.Eur J Cardiothorac Surg2022;61:449-56

[65] Spadaccio C.Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease: quo vadis?.Ann Cardiothorac Surg2018;7:506-15 PMCID:PMC6082779

[66] d’Entremont MA,Salia SJS.The effect of diabetes on surgical versus percutaneous left main revascularization outcomes: a systematic review and meta-analysis.J Cardiothorac Surg2022;17:61 PMCID:PMC8973812

[67] Head SJ,Daemen J.Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.Lancet2018;391:939-48

[68] Whicher CA,Holt RIG.Diabetes in the UK: 2019.Diabet Med2020;37:242-7

[69] Raza S,Ainkaran P.Coronary artery bypass grafting in diabetics: a growing health care cost crisis.J Thorac Cardiovasc Surg2015;150:304-2.e2 PMCID:PMC5120545

[70] Royse A,Pawanis Z.Patency of conduits in patients who received internal mammary artery, radial artery and saphenous vein grafts.BMC Cardiovasc Disord2020;20:148 PMCID:PMC7092416

[71] Ak E,Midi A.Histopathologic evaluation of saphenous vein grafts in patients with type II diabetes mellitus undergoing coronary artery bypass grafting.Cardiovasc Pathol2021;52:107328

[72] Martínez-González B,Quiroga-Garza A.Conduits used in coronary artery bypass grafting: a review of morphological studies.Ann Thorac Cardiovasc Surg2017;23:55-65 PMCID:PMC5422630

[73] Raza S,Houghtaling PL.Influence of diabetes on long-term coronary artery bypass graft patency.J Am Coll Cardiol2017;70:515-24

[74] Maltais S,Bell MR.Reoperation for coronary artery bypass grafting surgery: outcomes and considerations for expanding interventional procedures.Ann Thorac Surg2017;103:1886-92

[75] Sasaki Y,Becker AE,Ueda M.Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications.Heart2000;83:69-75 PMCID:PMC1729291

[76] Kockx MM,Bortier HE,Van Cauwelaert PA.The modulation of smooth muscle cell phenotype is an early event in human aorto-coronary saphenous vein grafts.Virchows Arch A Pathol Anat Histopathol1992;420:155-62

[77] Davies MG.Structural and functional consequences of bypass grafting with autologous vein.Cryobiology1994;31:63-70

[78] Muto A,Ziegler K,Dardik A.Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies.Circ J2010;74:1501-12 PMCID:PMC3662001

[79] Ishiko K,Akagami T.Hyperglycemia induced cell growth and gene expression via the serum response element through RhoA and Rho-kinase in vascular smooth muscle cells.Prep Biochem Biotechnol2010;40:139-51

[80] Chen GP,Wu T,Han J.Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process.J Diabetes Res2015;2015:379287 PMCID:PMC4396976

[81] Hemmings KE,Bailey MA,Turner NA.Role of microRNA-145 in DNA damage signalling and senescence in vascular smooth muscle cells of type 2 diabetic patients.Cells2021;10:919 PMCID:PMC8073820

[82] Madi HA,Warburton P,Turner NA.Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients.Am J Physiol Cell Physiol2009;297:C1307-17

[83] Riches K,Warburton P.Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function.J Mol Cell Cardiol2014;74:240-50 PMCID:PMC4121534

[84] Riches K,O'Regan DJ,Porter KE.Type 2 diabetes impairs venous, but not arterial smooth muscle cell function: possible role of differential RhoA activity.Cardiovasc Revasc Med2014;15:141-8 PMCID:PMC4121534

[85] Nagao T,Grosheva I,Pierini LM.Elevated cholesterol levels in the plasma membranes of macrophages inhibit migration by disrupting RhoA regulation.Arterioscler Thromb Vasc Biol2007;27:1596-602

[86] Wu W,Zang H.Mature vascular smooth muscle cells, but not endothelial cells, serve as the major cellular source of intimal hyperplasia in vein grafts.Arterioscler Thromb Vasc Biol2020;40:1870-90 PMCID:PMC7439253

[87] McCallum JE,Divorty N.G-protein-coupled receptor 35 mediates human saphenous vein vascular smooth muscle cell migration and endothelial cell proliferation.J Vasc Res2015;52:383-95 PMCID:PMC4959467

[88] Oliveira de Souza C, Sun X, Oh D. Metabolic functions of G protein-coupled receptors and β-arrestin-mediated signaling pathways in the pathophysiology of type 2 diabetes and obesity.Front Endocrinol2021;12:715877 PMCID:PMC8419444

[89] Arnold C,Feldner A.Hypertension-evoked RhoA activity in vascular smooth muscle cells requires RGS5.FASEB J2018;32:2021-35

[90] Ivanova EA,Orekhov AN.Intimal pericytes as the second line of immune defence in atherosclerosis.World J Cardiol2015;7:583-93 PMCID:PMC4620069

[91] Lechartier B,Huertas A,Guignabert C.Phenotypic diversity of vascular smooth muscle cells in pulmonary arterial hypertension: implications for therapy.Chest2022;161:219-31

[92] Tsapara A,Greenwood J,Matter K.The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration.Mol Biol Cell2010;21:860-70 PMCID:PMC2836967

[93] Qiao YC,Pan YH.Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a PRISMA-compliant systematic review and meta-analysis.Medicine2017;96:e6583 PMCID:PMC5403085

[94] Sakata N,Takebayashi S.Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells.J Atheroscler Thromb2000;7:169-76

[95] Yang H,Kuang SJ.Abnormal Ca²⁺ handling contributes to the impairment of aortic smooth muscle contractility in Zucker diabetic fatty rats.J Mol Cell Cardiol2020;141:82-92

[96] Brandes RP.Statin-mediated inhibition of Rho: only to get more no?.Circ Res2005;96:927-9

[97] Patel KK,Kashfi K.Molecular targets of statins and their potential side effects: Not all the glitter is gold.Eur J Pharmacol2022;922:174906 PMCID:PMC9007885

[98] Bonetti P.Statin effects beyond lipid lowering - are they clinically relevant?.Eur Heart J2003;24:225-48

[99] Ouyang QF,Lin ZH,Xu CS.Fluvastatin upregulates the α 1C subunit of CaV1.2 channel expression in vascular smooth muscle cells via RhoA and ERK/p38 MAPK pathways.Dis Markers2014;2014:237067 PMCID:PMC4295146

[100] Kang S,Kim K.Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin.Toxicol Sci2014;138:446-556

[101] Kang S,Noh JY.Simvastatin induces the apoptosis of normal vascular smooth muscle through the disruption of actin integrity via the impairment of RhoA/Rac-1 activity.Thromb Haemost2016;116:496-505

[102] Yandrapalli S,Guber K.Statins and the potential for higher diabetes mellitus risk.Expert Rev Clin Pharmacol2019;12:825-30

[103] Ozen G,Pedro S,Suissa S.Reduction of cardiovascular disease and mortality versus risk of new-onset diabetes mellitus with statin use in patients with rheumatoid arthritis.Arthritis Care Res2022;